Biotech Values

[rsox]

fuzeon sales seem to be picking up...

their one year estimate is 140 million to 150.... and they are at 55 million at the end of the first qtr, the first qtr according to their execs has been the weakest and was expected to be the weakest this year also.


http://biz.yahoo.com/ap/060510/earns_trimeris.html?.v=1

Trimeris Posts Narrower 1Q Loss
Wednesday May 10, 4:34 pm ET
Trimeris Posts Narrower 1st-Quarter Loss on Strong Sales of Fuzeon HIV Drug

MORRISVILLE, N.C. (AP) -- Biotech company Trimeris Inc. said Wednesday its first-quarter loss narrowed considerably as its revenue rose thanks to strong sales of Fuzeon, an HIV drug.
The company posted a loss of $428,000, or 2 cents per share, compared with a loss of $5.5 million, or 25 cents per share, during the same period a year ago. Excluding stock options costs, the company earned $643,000, or 3 cents per share.

Revenue and collaboration income was $7.4 million, compared with last year's $2.2 million.

Analysts, on average, were expecting a loss of 6 cents per share and revenue of $5.1 million, according to a poll by Thomson Financial.

Sales of Fuzeon are recorded by the company's collaborative partner, F. Hoffmann-La Roche Ltd., the U.S. prescription drugs unit of Swiss pharmaceutical company Roche Holding Ltd. The drug's worldwide sales were up 31 percent, to $55.4 million compared with the year-ago period.

Trimeris said it still expects to be profitable over the full year.

Fuzeon works by stopping HIV from fusing with human cells where anti-retroviral treatments have failed.

Shares rose 44 cents, or 4 percent, to $11.70 in after-hours electronic trading, having earlier closed at $11.26 on the Nasdaq.